
# RealRate

#### PHARMACEUTICAL 2019

### LIXTE BIOTECHNOLOGY HOLDINGS INC.

Rank 199 of 371



# RealRate

#### PHARMACEUTICAL 2019

### LIXTE BIOTECHNOLOGY HOLDINGS INC.

Rank 199 of 371

The relative strengths and weaknesses of LIXTE BIOTECHNOLOGY HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LIXTE BIOTECHNOLOGY HOLDINGS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 398% points. The greatest weakness of LIXTE BIOTECHNOLOGY HOLDINGS INC. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 262% points.

The company's Economic Capital Ratio, given in the ranking table, is -181%, being 150% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	4,334
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	211
Liabilities, Non-Current	0
Other Assets	2.3
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	4.9
Property and Equipment	0
Research and Development	41
Revenues	0
Selling, General and Administrative Expense	2,097

Output Variable	Value in 1000 USD
Assets	4,337
Liabilities	211
Expenses	2,138
Stockholders Equity	4,126
Net Income	-2,133
Comprehensive Net Income	-2,133
Economic Capital Ratio	-181%